Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry
Abstract
Until recently, inhibitors of tumour necrosis factor (TNFi) had been the only bDMARD treatment option for patients with axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A monoclonal antibody secukinumab (SEC) became available for treatment of spondyloarthritides.
It has been shown recently, that baseline patient characteristics may explain some of the differences in response to bDMARDs in PsA. In order to gain better understanding how the new treatment option is utilised in clinical practice we compared baseline characteristics of patient populations starting treatment with SEC versus TNFi during the first year of SEC availability in the Czech Republic using data from the ATTRA registry.